Table 8.
Clinical features | Proportion | Penetrance (%) |
---|---|---|
INFECTIONS (BACTERIAL/VIRAL/FUNGAL) | ||
Pulmonary | 6/6 | 100 |
Skin | 3/6 | 50 |
Gastrointestinal tract | 3/6 | 50 |
ORGAN INVOLVEMENT | ||
Periodontal disease | 6/6 | 100 |
Gastrointestinal inflammation | 5/6 | 83 |
Dermatitis | 4/6 | 67 |
DEVELOPMENT | ||
Failure to thrive | 5/6 | 83 |
Abnormal Facies | 3/6 | 50 |
LABORATORY TESTS | ||
Cell populations | ||
Normal lymphocytes numbers | 3/4 | 75 |
↓ Treg | 3/4 | 75 |
Normal B cells | 4/6 | 67 |
↑ CD3+, CD4+ T cells | 4/6 | 67 |
↑ CD8+ T cells | 3/5 | 60 |
Response | ||
↓ T cell proliferation (PHA, α-CD3/CD28) | 6/6 | 100 |
↓ NF-κB phosphorylation/IκBα degradation | 6/6 | 100 |
↓ IL-2 secretion | 6/6 | 100 |
Ig | ||
↓ specific antibodies | 3/4 | 75 |
↓ IgM | 3/6 | 50 |
↑ IgE | 3/6 | 50 |
Common features found in MALT1-deficient patients. Included are proportion of patients where data is available and the percentage of patients with that finding. ↑, increased levels relative to normal range; ↓, decreased levels relative to normal range.